智通财经APP获悉，北海康成-B(01228)再涨近17%，年内累计涨幅已超1500%。截至发稿，涨14.36%，报2.23港元，成交额4107.5万港元。
消息面上，北海康成近日公布，与百洋医药达成股份认购协议。百洋医药将以每股1.34港元的价格认购价值约1亿港元的北海康成股份。与此同时，北海康成与百洋医药双方通过签订独家商业化服务协议，进一步深化战略协同。根据协议，百洋医药旗下子公司将获得北海康成旗下特定产品在中国内地、香港及澳门地区的推广权。
此外，国家医保局8月12日公布商保创新药目录初审名单。北海康成三款罕见病产品均通过了商保创新药目录的形式审查。包括今年5月获批上市的用于12岁及以上青少年和成人I型和Ⅲ型戈谢病患者的长期酶替代产品戈芮宁（注射用维拉苷酶β）；用于治疗ALGS/PFIC胆汁淤积性瘙痒的迈芮倍（氯马昔巴特口服液）；用于治疗黏多糖贮积症II型的海芮思（艾度硫酸酯酶β注射液)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.